Drugs Monitor, Page 12

(06 Feb 2021) Tocilizumab- Combination therapy of TCZ and Steroids is likely to be safe and effective

February 16, 2021

Combination therapy of Tocilizumab and steroid for management of COVID-19 associated cytokine release syndrome: A single center experience from Pune, Western India https://www.medrxiv.org/content/10.1101/2021.02.04.21249959v1 Out of 2831 admitted patients, 515 (24.3% females) were administered TCZ and steroids. Median age of the… Continue reading "(06 Feb 2021) Tocilizumab- Combination therapy of TCZ and Steroids is likely to be safe and effective"

(06 Feb 2021) Azithromycin- did not improve survival or other prespecified clinical outcomes

February 16, 2021

Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial https://doi.org/10.1016/S0140-6736(21)00149-5 RECOVERY trial-NCT04381936. Between April 7 and Nov 27, 2020, of 16 442 patients enrolled in the RECOVERY trial, 9433 (57%) were eligible and 7763… Continue reading "(06 Feb 2021) Azithromycin- did not improve survival or other prespecified clinical outcomes"

(06 Feb 2021) Colchicine-reduced the length of both, supplemental oxygen therapy and hospitalisation

February 16, 2021

Beneficial effects of colchicine for moderate to severe COVID-19: a randomised, double-blinded, placebo-controlled clinical trial https://doi.org/10.1136/rmdopen-2020-001455 Trial number: RBR-8jyhxh- Seventy-two patients (36 for placebo and 36 for colchicine) completed the study. Median (and IQR) time of need for supplemental oxygen… Continue reading "(06 Feb 2021) Colchicine-reduced the length of both, supplemental oxygen therapy and hospitalisation"

(05 Feb 2021) Ivermectin- early viral clearance was observed

February 16, 2021

Efficacy of Ivermectin in COVID-19 Patients with Mild to Moderate Disease https://www.medrxiv.org/content/10.1101/2021.02.02.21250840v1 NCT04392713-A randomized clinical trial (Trial registration # NCT04392713) was carried out at Combined Military Hospital Lahore from March 15, 2020, to June 15, 2020. In group A, 36 (80%)… Continue reading "(05 Feb 2021) Ivermectin- early viral clearance was observed"

(05 Feb 2021) Methylprednisolone- decreased mortality as compared to dexamethasone

February 16, 2021

A Comparison of Methylprednisolone and Dexamethasone in Intensive Care Patients with COVID-19 https://www.medrxiv.org/content/10.1101/2021.02.03.21251088v1 This study retrospectively compares the effectiveness of methylprednisolone to dexamethasone in patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2 or COVID-19) requiring ICU care. A total… Continue reading "(05 Feb 2021) Methylprednisolone- decreased mortality as compared to dexamethasone"

(05 Feb 2021) Hydroxychlooquine- No beneficial effect or significant harm

February 16, 2021

HYDROXYCHLOROQUINE FOR THE TREATMENT OF SEVERE RESPIRATORY INFECTION BY COVID-19: A RANDOMIZED CONTROLLED TRIAL https://www.medrxiv.org/content/10.1101/2021.02.01.21250371v1 NCT04315896- A total of 214 patients with COVID-19 were recruited, randomized and analyzed. They were hypoxemic with a mean SpO2 of 65% ± 20, tachycardic… Continue reading "(05 Feb 2021) Hydroxychlooquine- No beneficial effect or significant harm"

(05 Feb 2021) Tocilizumab- associated with reduced hazards of death

February 16, 2021

Tocilizumab for the Treatment of COVID-19 Among Hospitalized Patients: A Matched Retrospective Cohort Analysis https://doi.org/10.1093/ofid/ofaa598 This was an observational retrospective study of hospitalized adult patients with confirmed coronavirus disease 2019 (COVID-19). The intervention group comprised patients who received tocilizumab; the… Continue reading "(05 Feb 2021) Tocilizumab- associated with reduced hazards of death"

(03 Feb 2021) Sarilumab- not found efficacious in COVID-19 hospitalized patients

February 5, 2021

Sarilumab treatment of hospitalised patients with severe or critical COVID-19: a multinational, randomised, adaptive, phase 3, double-blind, placebo-controlled trial https://www.medrxiv.org/content/10.1101/2021.02.01.21250769v1 NCT04327388- Between March 28 and July 3, 2020, 420 patients were randomised; 416 received treatment (placebo, n=84; sarilumab 200 mg,… Continue reading "(03 Feb 2021) Sarilumab- not found efficacious in COVID-19 hospitalized patients"

(03 Feb 2021) Sofosbuvir-added to the standard of care, SOF accelerated time to the clinical response

February 5, 2021

Efficacy and safety of sofosbuvir/ ledipasvir in treatment of patients with COVID-19; A randomized clinical trial https://doi.org/10.23750/abm.v91i4.10877 IRCT: 20100228003449N29- Clinical response occurred in 91.46% of patients. Although rates of clinical response were comparable between the groups but it occurred faster… Continue reading "(03 Feb 2021) Sofosbuvir-added to the standard of care, SOF accelerated time to the clinical response"

(01 Feb 2021) Tocilizumab- associated with reduced mortality and faster clinical improvement in patients with higher IL-6

February 5, 2021

Administration of tocilizumab to patients with high concentrations of IL-6 in the course of COVID-19 is associated with a better prognosis https://www.medrxiv.org/content/10.1101/2021.01.28.21249932v1 Patients treated with TCZ were balanced compared to non-TCZ regarding gender, age, BMI, and prevalence of coexisting conditions.… Continue reading "(01 Feb 2021) Tocilizumab- associated with reduced mortality and faster clinical improvement in patients with higher IL-6"